Skip to main content

Table 2 Validation studies for association of MICA with the risk of HCC development among chronic hepatitis patients

From: Main insights of genome wide association studies into HCV-related HCC

Study/year Ethnicity Cases/controls P value OR (95%CI)
Kumar 2012 [10] Japanese 407 HCC cases/699 CHB subjects and 5657 non-HBV controls 0.029 1.19 ( 1.02–1.4)
Lo 2013 [11] Japanese 1394 HCV-HCC/1629 LC-CHC 0.2
Lange 2013 [12] European 68 HCV-related HCC patients/1860 HCV patients 0.03 0.58 (0.35–0.95)
Chang 016 [13] Chinese 120 HCC/124 healthy controls 0.02 1.57(1.07–2.31)
Burza 2016 [14] European 192 LC-HCC/199 LC 0.34
Huang 2017 [15] Taiwanese Cohort of 705 patients receiving INF based antiviral therapy.
58 develop HCC/647 did not develop HCC
0.002 4·37(1.52–12.07)
Mohamed 2017 [16] Egyptian 47HCV-HCC/47HCV-LC and 47 healthy controls HCC vs. healthy 0.01 HCC vs. healthy
2.1 (1.17–3.78)
Hai 2017 [17] Japanese 142 HCV-HCC/575 HCV non-HCC patients 0.0002 4.47 (2.04–9.80)
Augello 2018 [18] Italian 154 HCV-HCC/93 HCV-LC and 244 healthy controls HCC VS controls = 0.03
HCC VS LC = 0.04
HCC VS controls
0.599 (0.371–0.968)
HCC VS LC
0.522 (0.276–0.989)
  1. CHB chronic hepatitis B, LC liver cirrhosis, CHC chronic hepatitis C